Next-gen IgH reprogramming for in vivo delivery
Official title: Next Generation IgH-reprogramming for in vivo delivery
Funded at Scripps Research Institute, the · NIH-11404857 · Data updated 2026-11-12
A research project at Scripps aims to safely insert HIV-neutralizing antibody instructions into B cells inside the body to create lasting protective immune responses.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scripps Research Institute, the NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | September 5, 2025 |
| Project end | June 30, 2030 |
| Funding year | 2026 |
| Award (this year) | $598,184 |
| NIH project number | 5P01HL183482-02 |
| Project ID | NIH-11404857 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be adults at risk for HIV or living with HIV who could benefit from future antibody-based therapies, pending further development and trials.
✕Less likely to help
People without HIV or those not eligible for future trials may not directly benefit from this specific research.
What this research studies
This grant explores new ways to edit B cells inside living organisms so they can produce HIV-fighting antibodies. Researchers will test precision genome editing methods that avoid dangerous breaks in DNA, and compare different delivery systems to reach B cells effectively. The work focuses on safety, feasibility, and steps toward eventual clinical use in people at risk of or living with HIV. The goal is to move closer to a durable, antibody-based defense against HIV through in vivo B cell engineering.
Why it matters
Potential benefit: If successful, this work could lead to a novel antibody-based strategy for durable HIV protection or treatment.
How similar studies have gone: Early studies in genome editing and B cell engineering show promise, but in vivo IgH reprogramming remains a developing area.
Where this research is happening
-
Scripps Research Institute, the
La Jolla, United States Active
Researchers
- Principal investigator: Miller, Shannon Marie — Scripps Research Institute, the
- Study coordinator: Miller, Shannon Marie
Related research
Other NIH-funded projects on the same topics.
-
The Participant Center helps people join and stay in a nationwide health study
A nationwide program to support people in joining, contributing biosamples, and staying connected to a large health study in the United States.
-
Data Sharing and Bioinformatics Core for Viral Systems Biology
A center-led effort to manage, share, and interpret large viral systems biology data using open tools and a community-friendly portal.
-
Germline-targeted HIV vaccines using membrane liposome tech to trigger bnAbs
A new HIV vaccine approach aims to spark broadly neutralizing antibodies by showing MPER on membranes, tested in models and early studies to guide future human trials.
-
Antivirals for hemorrhagic fever viruses like LASV, SFTSV, and EBOV
A multi-institutional effort to find and validate antiviral compounds that block key viral proteins from LASV, SFTSV, and EBOV to help people at risk from serious hemorrhagic fevers.
-
Developing new antivirals for flaviviruses
A research team is working to create oral antiviral drugs targeting flaviviruses to treat infections that affect millions of people.
-
CoV inhibitors targeting non-enzymatic SARS-CoV-2 components
A multicenter research effort seeks antiviral ideas that block SARS-CoV-2 parts that don’t work through traditional enzymes, aiming to help people affected by COVID-19.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.